The National Institute for Health and Clinical Excellence (NICE) has issued guidance on the use of eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura. The following recommendations have been made (taken directly from source):

• Eltrombopag is not recommended within its marketing authorisation for the treatment of chronic immune (idiopathic) thrombocytopenic purpura:

- in splenectomised adults whose condition is refractory to other treatments (for example, corticosteroids, immunoglobulins) or
- as second-line treatment in non-splenectomised adults where surgery is contraindicated.

• People currently receiving eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura should have the option to continue treatment until they and their clinician consider it appropriate to stop.